clinical trial · NCT06152861
Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension
Open Angle GlaucomaOcular HypertensionTravoprost Ophthalmic Topical Cream low-doseTravoprost Ophthalmic Topical Cream mid-doseTravoprost Ophthalmic Topical Cream high-doseTimolol maleate ophthalmic solution, 0.5%Travoprost Ophthalmic Solution, 0.004%
brief summary
The goal of this clinical trial is to learn about the safety of Travoprost Ophthalmic Topical Cream and how well it works in lowering high intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). A low dose, medium dose and high dose of Travoprost Ophthalmic Topical Cream will be compared to timolol maleate ophthalmic solution, 0.5% and to travoprost ophthalmic solution, 0.004%.
started
Nov 15, 2023
primary completion
Aug 1, 2024
completion
Aug 1, 2024
last updated
Dec 6, 2023
official title
Multicenter, Randomized, Double-Masked, Active-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Travoprost Ophthalmic Topical Cream in Subjects With Open-angle Glaucoma or Ocular Hypertension
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol